Mandate

Vinge advises Cellink in directed new issues of shares of MSEK 946

Vinge has advised Cellink in connection with directed new issues of shares of approximately 5.9 million class B shares which will generate MSEK 946 for Cellink.

The subscription price has been set through a so‑called accelerating book building procedure performed by Carnegie and J.P. Morgan and corresponds to a discount of 1.7% compared to the share’s closing date rate on Nasdaq Stockholm. Almost 4.3 million shares have been issued by virtue of the authorization resolved by the general meeting and approximately 1.6 million shares have been issued conditional upon approval by an extraordinary general meeting. The purpose of the new issues of shares is, in part, financing of the cash element of the purchase price for the acquisition of Scienion Ag., and, in part, to create scope for Cellink’s continued M&A agenda.

Vinge’s team primarily consisted of Anders StridEdin Agic and Victoria Gunnerek.

Related

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026

Vinge has advised Skeptiva AB in connection with its financing round

Skeptiva is developing the next generation of cybersecurity defenses against fraud. The company has developed an AI application that detects attacks and alerts users in real time.
March 11, 2026

Vinge has advised Main Capital in connection with the acquisition of Good Solutions Sweden AB

Good Solutions Sweden AB (”Good Solutions”) provides software that helps factories identify and reduce production losses. The software converts data from machines and operators into insights that can be used to streamline production and increase profitability.
March 11, 2026